(1.12%) 5 104.94 points
(0.34%) 38 214 points
(2.13%) 15 944 points
(-0.14%) $83.45
(-1.28%) $1.617
(0.17%) $2 346.50
(-0.21%) $27.30
(0.12%) $921.60
(0.48%) $0.936
(0.69%) $11.03
(0.36%) $0.802
(0.23%) $92.38
@ $40.50
Išleistas: 9 bal. 2024 @ 16:36
Grąža: -4.43%
Ankstesnis signalas: bal. 8 - 19:23
Ankstesnis signalas:
Grąža: 0.25 %
Live Chart Being Loaded With Signals
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 58 788.00 |
Vidutinė apimtis | 1.02M |
Rinkos kapitalizacija | 4.92B |
EPS | $0 ( 2024-02-20 ) |
Kita pelno data | ( $0.690 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 18.43 |
ATR14 | $0.0410 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-25 | Krishnan Mahesh | Buy | 0 | |
2024-04-17 | Labarre Michael J. | Buy | 10 000 | Common Stock |
2024-04-16 | Labarre Michael J. | Sell | 10 000 | Common Stock |
2024-04-17 | Labarre Michael J. | Sell | 10 000 | Common Stock |
2024-04-16 | Labarre Michael J. | Sell | 10 000 | Option to Purchase Common Stock |
INSIDER POWER |
---|
16.77 |
Last 99 transactions |
Buy: 612 606 | Sell: 439 990 |
Tūris Koreliacija
Halozyme Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
LWAC | 0.957 |
SRAC | 0.91 |
NETE | 0.889 |
AMRB | 0.889 |
ACER | 0.853 |
HOUR | 0.849 |
KNSA | 0.839 |
MMAC | 0.831 |
EEIQ | 0.829 |
WBA | 0.829 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
TLGT | -0.945 |
SVAC | -0.942 |
GOODM | -0.919 |
SIBN | -0.88 |
RPHM | -0.88 |
PAIC | -0.872 |
SNPO | -0.86 |
MTSL | -0.85 |
PYXS | -0.845 |
XOG | -0.843 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Halozyme Therapeutics Inc Koreliacija - Valiuta/Žaliavos
Halozyme Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $829.25M |
Bruto pelnas: | $636.89M (76.80 %) |
EPS: | $2.13 |
FY | 2023 |
Pajamos: | $829.25M |
Bruto pelnas: | $636.89M (76.80 %) |
EPS: | $2.13 |
FY | 2022 |
Pajamos: | $660.12M |
Bruto pelnas: | $520.81M (78.90 %) |
EPS: | $1.480 |
FY | 2021 |
Pajamos: | $443.31M |
Bruto pelnas: | $361.90M (81.64 %) |
EPS: | $2.84 |
Financial Reports:
No articles found.
Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.